Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Mayo Clinic
M.D. Anderson Cancer Center
Kaiser Permanente
Washington University School of Medicine
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Alliance for Clinical Trials in Oncology
University of California, Davis
City of Hope Medical Center
University of Nebraska
University Health Network, Toronto
The Netherlands Cancer Institute
University of Pittsburgh
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Cancer Research UK
West China Hospital
Petrov, Andrey
University of Pittsburgh
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Institut Cancerologie de l'Ouest
Milton S. Hershey Medical Center
NuCana plc
Azienda Ospedaliera di Padova
Providence Health & Services
University of California, San Diego
Oslo University Hospital
UNICANCER
University of Colorado, Denver
Thomas Jefferson University
Thomas Jefferson University
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
University Medical Center Groningen
Providence Health & Services
The Methodist Hospital Research Institute
Inova Health Care Services
Sheffield Teaching Hospitals NHS Foundation Trust
UNICANCER
University of Pittsburgh
University Health Network, Toronto
University Health Network, Toronto
The Netherlands Cancer Institute
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cedars-Sinai Medical Center
University of California, San Francisco